Patents by Inventor Hidetoshi Emi

Hidetoshi Emi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180280293
    Abstract: Disclosed herein is a pharmaceutical composition for skin that is a preparation containing a vitamin D3 compound and a corticosteroid as active ingredients, that is excellent in the stability of each of the active ingredients, and that has appropriate transdermal absorbability of the active ingredients. The composition is a non-aqueous composition for skin comprising: (a) maxacalcitol; (b) at least one corticosteroid selected from the group consisting of betamethasone and esters thereof; (c) at least one low-polarity ester oil having an IOB value of 0.07 or more but less than 0.20; and (d) at least one non-polar liquid solvent.
    Type: Application
    Filed: November 17, 2015
    Publication date: October 4, 2018
    Inventors: Hidetoshi EMI, Masahiro FUJII
  • Patent number: 9555025
    Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: January 31, 2017
    Assignees: Maruho Co., Ltd., Mitsubishi Tanabe Pharma Corporation
    Inventors: Tomoki Sakaguchi, Hidetoshi Emi
  • Publication number: 20140018387
    Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene•3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.
    Type: Application
    Filed: March 28, 2012
    Publication date: January 16, 2014
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventors: Tomoki Sakaguchi, Hidetoshi Emi